

2021 DISCLOSURE OF INTEREST INFORMATION

GINA ASSEMBLY

Jorge Máspero, Argentina

Hugo Neffen, Argentina

Bennoor Kazi, Bangladesh

Mostafizur Rahman, Bangladesh

Rudi Peche, Belgium

Guy Joos, Belgium

Renaud Louis, Belgium

Rafael Stelmach, Brazil

Alvaro Cruz, Brazil

Todor Popov, Bulgaria

Wan-Cheng Tan, Canada

Chuanhe Liu, China

Jiangtao Lin, China

Yuzhi Chen, China

Lan Tuyet, Comtetae

Manuel Soto-Quiros, Costa Rica

Vibeke Backer, Denmark

Hesham Tarraf, Egypt

Mona El Falaki, Egypt

Maia Gotua, Georgia

JC Virchow, Germany

Allen Steele- Dadzie, Ghana

Faisal Yunus, Indonesia

Dr. Kshitij Agarwal, India

Babak Ghalehbaghi, Iran

Mohammad Ashkan Moslehi, Iran

Marcus W. Butler, Ireland

Patrick Manning, Ireland

Giorgio Walter Canonica, Italy

Pierluigi Paggiaro, Italy

Ken Ohta, Japan

Motohiro Ebisawa, Japan

Haytham El-Khushman, Jordan

Ra'ed Suleiman, Jordan

Zhanat Ispayeva, Kazakhstan

Damilya Nugmanova, Kazakhstan

Tair Nurpeissov, Kazakhstan

Yeon Mok Oh, Korea, Republic of

Ki-Suck Jung, Korea, Republic of

Aziz Koleilat, Lebanon

Carlos Jimenez, Mexico

Désirée Larenas-Linnemann M.D., Mexico

Richard Beasley, New Zealand

Javaid Khan, Pakistan

Osman Yusuf, Pakistan

Ewa Nizankowska, Poland

Florin Mihaltan, Romania

Ruxendra Ulmeanu, Romania

Alexander Chuchalin, Russia

Zaurbek Aisanov, Russia

Mohammed Al Ghobain, Saudi Arabia

TK Lim, Singapore

Vicente Plaza, Spain

Joaquin Sastre, Spain

Jing-Long Huang, Taiwan

Sateesh Sakhamuri, Trinidad And Tobago

Ipek Oguzulgen, Turkey

Mohammad Osman, United Arab Emirates

Mark Levy, United Kingdom

David Jackson, United Kingdom

B. Louise Giles, United States

Chau Ngo Quy, Vietnam

Sy Duong-Quy, Vietnam

Le Thi Tuyet Lan, Vietnam

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF FINANCIAL INTEREST

January 1, 2021 - December 31, 2021

Background

The Global Initiative for Asthma (GINA) program is a collaboration between the scientific community and the private sector. The major objectives are: (1) to increase awareness of asthma among health professionals, health authorities, and the general public; (2) improve diagnosis, management, and prevention; and (3) stimulate research. These objectives are being met through preparation of scientific reports on asthma, dissemination and adoption of recommendations in these reports, and promotion of international collaboration on asthma research.

The purpose of this document is to safeguard the interests of all GINA collaborators by an open disclosure of interests.

GINA Structure

At present, the GINA program is conducted through a GINA Board of Directors that meets annually (usually in January), a Scientific Committee and a Dissemination Committee. Each Committee will have an active role in reviewing and recommending content for GINA documents and all members will be asked to complete this form.

Annual Declaration of Interests

The following declarations are requested by GINA. Please complete the company name select in the corresponding box whether you have financial relationships (received grants, personal fees, shares, non-financial support, other). Please include all companies in the bio-medical arena, as well as telehealth/technology, and tobacco entities. This form will be posted on the GINA website after completion.

Definitions:

- 1. **Grants:** refers to any grant paid to your organization.
- 2. **Personal Fees:** refers to honorarium, consultation fees, etc for lectures, advisory committees or consultancy services either intermittent or regular, from which a GINA member benefits personally. This includes ongoing attendance at advisory board meetings but would not normally include a situation where an individual is paid for a specific item or for attending or speaking at an occasional meeting.
- 3. **Shares:** refers to any shares in asthma-related commercial organizations, excluding unit trusts, pension plans or mutual funds, and it refers to shares held by a GINA member or family members (spouse/children). The company is to be listed, not the number of shares.
- 4. **Non-Financial Support:** In-kind assistance.

The private sector should not in any way be involved in any aspect of developing documents, including collecting, reviewing or accessing the literature or determining the content. Once documents have been produced asthma-related commercial organizations can be involved in their dissemination and audit, including support for publications.



Name: JORGE FERNANDO MASPERO
Member of (choose one or more):

☐ GINA Board of Directors
☐ GINA Science Committee
☐ GINA Dissemination & Implementation Task Group X GINA Advocate
X GINA Assembly

Are there any relevant financial interests to disclose? YES

Name of Entity	Grant?	Personal	Non-Financial	Other?	Nature of
Name of Entity	Grant.	Fee?	Support?	Other.	involvement:
					RESEACH
					GRANTS PAID TO
					INSTITUTION,
					SPEAKER FEES,
CANOCI	v	V	v		WRITING
SANOFI	X	X	X		ASSISTANCE RESEACH
					GRANTS PAID TO
					INSTITUTION,
					SPEAKER FEES,
					WRITING
ASTRA ZENECA	X	X	X		ASSISTANCE
					RESEACH
					GRANTS PAID TO
					INSTITUTION, SPEAKER FEES ,
					WRITING
NOVARTIS	X	X	X		ASSISTANCE
					RESEACH
					GRANTS PAID TO
					INSTITUTION,
					SPEAKER FEES,
GSK	v	V	v		WRITING
GSK	X	X	X		ASSISTANCE RESEACH
					GRANTS PAID TO
MSD	X				INSTITUTION
URIACH		X			SPEAKER FEES
MENARINI		X			SPEAKER FEES
ABBVIE		X			SPEAKER FEES
					RESEACH
					GRANTS PAID TO
ELLI LILLY	X				INSTITUTION

TOBACCO INDUSTRY FUNDING

X I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies.

Signature:

Date: JANUARY 17, 2022



ame: Hugo Eduardo Neffen
Iember of (choose one or more):
I GINA Board of Directors
I GINA Science Committee
GINA Dissemination & Implementation Task Group
GINA Advocate
GINA Assembly
re there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Novartis Colombia		X			Lecturer
GSK Argentina		X			Lecturer-Advisory Committee
ELEA Argentina		X			Lecturer

TOBACCO INDUSTRY FUNDING

X I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies.

electronic nicotine delivery syst	tem companies that are wholly or partially owne
Signature:	
Date:January 18 th , 2022_	



e there any relevant finan Name of Entity	Grant?	Personal	Non-Financial	Other?	Nature of
		Fee?	Support?		involvement:



there any relevant financial interests to disclose? Name of Entity Grant? Personal Fee? Sup				Other?	Nature of involvement:



Name of Entity	Grant?	Personal	Non-Financial	Other?	Nature of
		Fee?	Support?		involvement:
AstraZeneca	X				All fees were paid t the University
Chiesi	X				"
GlaxoSmithKline	X	X			"
Novartis		X			"
ALK		X			"
					



GLOBAL INITIATIVE FOR ASTHMA (GINA)_ DISCLOSURE OF INTEREST

FOR THE PERIOD Jan 1, 2020 - <u>2021</u>	to _Dec 31, 20202021
Name: DR PECTE RUBI	
Member of (choose one or more): ☐ GINA Board of Directors ☐ GINA Science Committee ☐ GINA Dissemination & Implementation Task Group ☐ GINA Advocate ☐ GINA Assembly	
Are there any relevant financial interests to disclose?-	

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
ASTA ZENECA		X			SEAKEN / ADUISAY
Case 2,		X			SUBAKAN MUZERY
Wathingen Incorpoin		×		·	SPEATZEN/THSKED
2 France		X			SPEAKER
GSK		×		-	Chermen Hursen
SANJE!		L			tomas unativet
				_	

	
TOBACCO INDUSTRY FUNDING	NO
/	"STH
I declare that in the last 5 years, I have nelectronic nicotine delivery system companion	not received any funding from the tobacco industry or from nies that are wholly or partially owned by tobacco companies.
Signature:	
Date: 02 02 22	



ember of (choose one or mo	re).				
GINA Board of Directors	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
GINA Science Committee					
GINA Dissemination & Im GINA Advocate	plementat	ion Task G	roup		
GINA Assembly					
011111111111111111111111111111111111111					
e there any relevant financi					
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
PROAK FOUNDATED	N NO	NO	V		PRESIDENT
ASTMAZENERA	V				ADVISOR
ASTRA ZENEEA		\vee			LEGUMEN
65K		V.			AOVESORY
GSK	7	V			LACTUPES.
BOEHNENDER		V			ADVIJOIM
	_				
1					
					1
I					
4					

Signature:



Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement
No	No	No	No	No	No
The state of the state of		Mary Street	THE RELEASE		ny manipula
				1489	
TYAN SO THE S			and the same	Control to	
		1		STATE OF	To do com
				10. 100 71	
				BLOWN A	PARTICIPAL DE LA CONTRACTION DEL CONTRACTION DE LA CONTRACTION DE
Did Stille				7/11/5/11/0	10000
				رُ رَمْنُسِي	
					Sale St
U.S.		Townships			
					The later of the l



Name:Chen Yuzhi					
Member of (choose one or mo ☐ GINA Board of Directors ☐ GINA Science Committee ☐ GINA Dissemination & Im ☐ GINA Advocate ✓ GINA Assembly Are there any relevant financi	plementat		-		
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
TOBACCO INDUSTRY FU √ I declare that in the last 5 yea electronic nicotine delivery systematics.	ırs, I have n				
Signature: Chen Yuzhi					
Date: 2022.1.20					



Name: Le Thi Tuyet Lan	
Member of (choose one or more):	
☐ GINA Board of Directors	
☐ GINA Science Committee	
☐ GINA Dissemination & Implementation Task Gro	oup
☐ GINA Advocate	•
☑ GINA Assembly	

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
AstraZeneca	No	Yes	No	No	Honoraria
Boehringer Ingelheim	No	Yes	No	No	Honoraria
GlaxoSmithKline	No	Yes	No	No	Honoraria
Novartis	No	Yes	No	No	Honoraria

TOBACCO INDUSTRY FUNDING

☑ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies.

Signature:

Date: 18th Jan 2022



N	ame: _Prof Hesham Tar	rraf <i>MD FRCPE</i>								
	dember of (choose one of GINA Board of Direct GINA Science Commit GINA Dissemination & GINA Advocate GINA Assembly are there any relevant fin	ors ttee & Implementation	-)						
	Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:				
			received speaker honoraria from Novartis, Astra- Zeneca,	Support		involvement:				
	speaker fees		BI, MSD							
	Expert consultation fees		GSK							
-	Congress funding	9 pharmaceuticals								
-										
9	☑ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies. Signature:hesham Tarraf Date:2-4-2022									



Name: MAIA GOTUA	Prof. MD. PGD.
Member of (choose one or more): ☐ GINA Board of Directors ☐ GINA Science Committee	
GINA Dissemination & Implementation Task Group	
☐ GINA Advocate ☐ GINA Assembly	

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
no	no	ho	no	no	no

TOBACCO INDUSTRY FUNDING

I declare that in the last 5 years, I have not received any funding from the tobacco industry or from	n
electronic nicotine delivery system companies that are wholly or partially owned by tobacco compan	ies



Name: <u>Dr. Kshitij Agarwal</u>					
Member of (choose one or mo ☐ GINA Board of Directors ☐ GINA Science Committee ☐ GINA Dissemination & Im ☐ GINA Advocate ☐ GINA Assembly	nplementat		-	doglarad	
Are there any relevant financi Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Not Applicable	NA	NA	NA	NA	NA
				<u> </u>	
TOBACCO INDUSTRY FU I declare that in the last 5 year electronic nicotine delivery system Signature:	rs, I have n em compan			the tobacco owned by	o industry or from tobacco companies.
Date: 18 January 2022					



□ GINA □ GINA □ GINA	of (choose one or mo Board of Directors Science Committee Dissemination & Im		ion Task Gi	-oup		
☑ GINA Are there	Advocate Assembly any relevant financi					
	Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
I decla	are that in the last 5 years inicotine delivery syste	rs, I have n	ot received a ies that are w	ny funding from the really or partially	the tobacco	industry or from tobacco companies.
Signatur	e:					
Data: Ja	anuary, 8 - 2022					



Name of Entity	nancial interests Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
		ree:	Support		mvorvement.



Name:Babak Ghalehba	ghi				
Member of (choose one or red) GINA Board of Directors GINA Science Committe GINA Dissemination & I GINA Advocate GINA Assembly	s ee Implementat		-		
Are there any relevant finan Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
					-
_					
OBACCO INDUSTRY F I declare that in the last 5 yelectronic nicotine delivery systems.	ears, I have n	ot received a	any funding from the vholly or partially	the tobacco owned by t	industry or from obacco companies.
ignature:Babak Ghaleh	baghi				



			E 9	C49		• 1		
	Name of Entity	Grant?	Personal	Non-Financial	Other?	Natui		
A	Are there any relevant financial interests to disclose?							
	ž							
	GINA Assembly							
X	GINA Advocate	-		-				
	GINA Dissemination & Im	plementat	ion Task Gı	oup				
	☐ GINA Science Committee							
	GINA Board of Directors							
١	Member of (choose one or mo	ore):						
	S							
\	Iame: Giorgio Walter CANO	NICA						

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
SANOFI	X				
SANOFI		X			AdvBoard-Speaker
Menarini		X			AdvBoard-Speaker
AstraZeneca	X				
AstraZeneca		X			AdvBoard-Speaker
Chiesi	X				
Chiesi		X			AdvBoard-Speaker
GSK	X				
GSK		X			AdvBoard-Speaker
Hal-Allergy	X				
Novartis	x				
Novartis		X			AdvBoard-Speaker
Stallergens-Greer	X				
Stallergens-Greer		X			AdvBoard-Speaker
Thermofisher		X			AdvBoard-Speaker

TOBACCO INDUSTRY FUNDING

XI declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies.

Signature:	
Date: _January 22, 2022	



NA Board of Director NA Science Committ NA Dissemination & NA Advocate NA Assembly	ee Implementat				
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
2	No	No	No	No	No
	FUNDING				



Name: Dr. Tair Nurpeissov

Member of (choose one or more):

☐ GINA Board of Directors

☐ GINA Science Committee

☐ GINA Dissemination & Implementation Task Group

GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Nature of involvement:
Astrazeneca	No	Yes	<u>No</u>	Yes	Presentation
<u>Egis</u>	No	Yes	<u>No</u>	No	Presentation
Kusum pharm	No	Yes	<u>No</u>	No	Presentation
Adamed pharm	No	Yes	<u>No</u>	No	Presentation
<u>Teva</u>	No	Yes	<u>No</u>	No	Presentation
Orion pharm	No	Yes	<u>No</u>	Yes	Presentation

TOBACCO INDUSTRY FUNDING

I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature

Date: 2021.01.18



Name:Yeon-N	Iok Oh				
Member of (choose one or n ☐ GINA Board of Directors ☐ GINA Science Committe ☐ GINA Dissemination & I ☑ GINA Advocate ☑ GINA Assembly	e mplementa				
Are there any relevant finance Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
GSK KOREA	No	Yes	No	No	Personal Fees (honorarium)
Novartis Korea	No	Yes	No	No	Personal Fees (honorarium)
Boehringer Ingelheim Korea	No	Yes	No	No	Personal Fees (honorarium)
TOBACCO INDUSTRY F ✓ I declare that in the last 5 ye electronic nicotine delivery sys Signature Yeon-Mok C Date:20 Feb. 2022	ears, I have retem compar	nies that are v	vholly or partially		



Name: Désirée E. S. Laren	as Linner	mann			
Member of (choose one or mo ☐ GINA Board of Directors ☐ GINA Science Committee ☐ GINA Dissemination & Im ☐ GINA Advocate ☐ GINA Assembly Are there any relevant financi	nplementat		meet with	also forr them)	m part of this group, as we do
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
GSK, AZ, Sanofi, Novartis	XX	XX	xx		Speaker,grant for guideline, Adboard
Lilly, Pfizer	xx				Grant for guideline
Abvvie	xx				Grant for guideline
Bayer, Siegfried, Viatris		XX			Speaker
Chiesi		xx			Medical education material I mad

TOBACCO INDUSTRY FUNDING

✓ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies.
Signature:
Data: January 19th 2022



Name:RICHARD BEASL	EY				_
Member of (choose one or mor ☐ GINA Board of Directors ☐ GINA Science Committee ☐ GINA Dissemination & Imp ☐X GINA Advocate ☐X GINA Assembly	olementatio				
Are there any relevant financia	al interests	to disclose?			
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
AstraZeneca	yes	yes	yes		Grants and supply of medications for clinical trials; personal fees for adboards and presentations at meetings
	,	, ,	, , , ,		Personal fees for presentations as
Cipla		yes			meeting
Genentech	yes				Grants for clinical trials
TOBACCO INDUSTRY FULL X I declare that in the last 5 ye electronic nicotine delivery system	ars, I have 1				
R: mand	Beau	7			
Signature:					
Date: _19/01/2022					



Name:					
Member of (choose one or moder of GINA Board of Directors GINA Science Committee GINA Dissemination & Important GINA Advocate GINA Assembly Are there any relevant financial	plementat				
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Received grant from CFTFK AND ASTRA FOR RESEARCH ON SMOKELESS TOBACCO					RESEARCH WORK
TOBACCO INDUSTRY FU ☐ I declare that in the last 5 yea electronic nicotine delivery systematics. Signature:	rs, I have nem compani	ies that are w	holly or partially	owned by	
Date:					



GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF INTEREST

FOR THE PERIOD Jan 1, 2021 to Dec 31, 2021

lame: OSMAN MOHAMMAD YUSUF	
Member of (choose one or more):	
GINA Board of Directors	
GINA Science Committee	
GINA Assembly	
·	

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non- Financial Support?	Other?	Nature of involvement:
RESPIRE, University of Edinburgh, Edinburgh, UK	V	$\sqrt{}$	$\sqrt{}$		Academic research as Principal Investigator. No commercial involvement of any kind.

TOBACCO INDUSTRY FUNDING

 \sqrt{I} declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies

Signature

Date: 16 March, 2022



Name:					
Member of (choose one or n ☐ GINA Board of Directors ☐ GINA Science Committe ☐ GINA Dissemination & I ☐ GINA Advocate ☐ GINA Assembly	e e	ion Task Gi	roup		
Are there any relevant finan-	cial interest	s to disclose Personal	? Non-Financial	Other?	Nature of
		Fee?	Support?		involvement:
			1		
TOBACCO INDUSTRY F ☐ I declare that in the last 5 ye electronic nicotine delivery sys	ears, I have n				
Signature: Ewo Nièc	enkowsk	۷		<i>,</i>	1
Date:					



e there any relevant finance Name of Entity	Grant?	s to disclose Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
AstraZeneca		yes			lecture
Boehringer Ingelheim		yes			lecture
Novartis		yes			lecture
Sandoz		yes			lecture
Sanofi		yes			lecture
inde		yes			lecture
MSD		yes			lecture



e there any relevant financ	ial interests	s to disclose	?		
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvemen
Chiesi Romania				Consultation fees	
Angelini Pharmaceuticals				Consultation fees	
AstraZeneca Pharma				Consultation fees	
Boehringer Ingelheim				Consultation fees	
Berlin Chemie				Consultation fees	
MSD Romania				Consultation fees	
Novartis Pharma Services Romania				Consultation fees	
Sandoz Romania				Consultation fees	
Sanofi Romania				Consultation fees	

TORACCO INDUSTRY FUNDING

Name: Ruxandra Ulmeanu

Member of (choose one or more):

☐ GINA Board of Directors

TOBACCO INDESTRI PENDING
I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies.
Signature:
Date: 66-4PR-2022



Name: _	Zaurbek Aisanov					
☐ GINA☐ GINA☐ GINA☐ GINA☐ GINA☐ GINA☐	of (choose one or mo A Board of Directors A Science Committee A Dissemination & Im A Advocate A Assembly	plementat				
Are there	e any relevant financi	al interests	s to disclose	e ?		
	Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
No		No	No	No	No	No
☑ I declared lectronic	are that in the last 5 year nicotine delivery system	rs, I have n				
Signatur	·. — ///					
Date:	18-MAR-2022					



Name: _	Mohammed	41 Ghib	gin/Saudi	Arabig
	of (choose one or more):		,	
☐ GINA	Board of Directors			
☐ GINA	Science Committee			
☐ GINA	Dissemination & Implen	nentation Task Group	D	
☐ GINA	Advocate			
☑ GINA	Assembly			
A ab		t. t. 1:10	NO	
-	e any relevant financial in		on-Financial Other?	Nature of

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
_/					

TOBACCO INDUSTRY FUNDING

declare t	hat in the last 5 years, I have not received any funding from the tobacco industry or from
electronic nic	otine delivery system companies that are wholly or partially owned by tobacco companies.
Signature: _	
	02/11/2022
Date:	23/1/0



Nature of involvement:

GLOBAL INITIATIVE FOR ASTHMA (GINA) DISCLOSURE OF INTEREST FOR THE PERIOD Jan 01, 2021 to Dec 31, 2021

Name: _Vicente PLAZA Member of (choose one or mo □ GINA Board of Directors □ GINA Science Committee	,				
X □ GINA Assembly					
Are there any relevant financ	ial interest	s to disclose	?		
Name of Entity	Grant?	Personal	Non-	Other?	
		Fee?	Financial Support?		
Astrazeneca		X			L
C1					_

			Support?	
Astrazeneca		X		Lecture
Glaxo		X		Consultant
Chiesi		X		Lecture
Astrazeneca		X		Consultant
Sanofi		X		Consultant
Chiesi	X			Support for research

TOBACCO INDUS	TRY FUNDING
	the last 5 years, I have not received any funding from the tobacco industry or ine delivery system companies that are wholly or partially owned by tobacco
	In
Signature	

Date: __March 18, 2020_____



Name: JOAQUIN SASTRE
Member of (choose one or more): □ GINA Board of Directors
☑ GIVA Board of Directors ☑ GINA Science Committee ☑ GINA Dissemination & Implementation Task Group
☑ GINA Advocate ☑ GINA Assembly

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
SANOFI	Х	Χ			Grant, paid lectures
GSK		Х			Paid lectures
Novartis		х			Board
Mundipharma		х			Paid lectures
ALK		Х			Paid lectures
URIACH		Χ			Paid lectures
FAES FARMA		Χ			Paid lectures

TOBACCO INDUSTRY FUNDING

🛛 I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies.

Signature:	- hee

Date: January 17, 2022



ber of (choose one or	more):				
NA Board of Director NA Science Committee	'S				
NA Dissemination &		ion Task G	roun		
NA Advocate	<u>-</u>		. o u p		
NA Assembly					
here any relevant finar	ncial interests	s to disclose	2?		
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
	Control Management of the Company		1.1		

TOBACCO INDUSTRY FUNDING

Name: ____Jing-Long Huang

☑ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from	n
electronic nicotine delivery system companies that are wholly or partially owned by tobacco compan	ies

Signature

Date: 2022, 02, 08



FOR THE PERIOD Jan 1, 2021 to Dec 31, 2021

N	Name: Dr. Sateesh Sakhamur	i				
	Member of (choose one or model) GINA Board of Directors GINA Science Committee GINA Dissemination & In GINA Advocate GINA Assembly Are there any relevant finance	nplementat		-		
	Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
	GlaxoSmithKline Caribbean Limited	No	Yes	No	No	Participated in the Advisory Board and pre-reading activities on 15th April 2021
						•
e	I declare that in the last 5 year lectronic nicotine delivery syst signature:	ars, I have n em compan				
	Signature: 20/01/2022					



Name:______Ipek Kivilcim Oguzulgen

Member of (choose one or more): ☐ GINA Board of Directors ☐ GINA Science Committee ☐ GINA Dissemination & Implementation Task Group ☐ GINA Advocate ☐-X GINA Assembly Are there any relevant financial interests to disclose?						
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:	
<u>GSK</u>	<u>X</u>	<u>X</u>			Ad committee, lecture	
DEVA Pharmaceuticals		<u>X</u>			Ad committee, Lecture	
Abdi İbrahim Pharmaceuticals		X			Lecture	
Chiesi Pharmaceuticals		<u>X</u>			Ad committee, Lecture	
Astra Zeneca Pharmaceuticals		X			Lecture	
<u></u>					2500000	

TOBACCO INDU	JSTRY FUNDING	3
	•	nave not received any funding from the tobacco industry or from panies that are wholly or partially owned by tobacco companies.

Date: _____24.03.2022



Name:DAVID JACKSC	N				
Member of (choose one or mo ☐ GINA Board of Directors ☐ GINA Science Committee ☐ GINA Dissemination & Im ☐ GINA Advocate X GINA Assembly Are there any relevant financi	plementat		•		
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Astrazeneca		X	• • • • • • • • • • • • • • • • • • • •		Speaker fees and advisory board fees
GSK		X			Speaker fees and advisory board fees
Sanofi Regeneron		X			Speaker fees and advisory board fees
TOBACCO INDUSTRY FU X I declare that in the last 5 year electronic nicotine delivery syste	rs, I have no em compan	ies that are w	holly or partially		
Signature:					
Date:4/4/22					



Name: B. Louise Giles					
Member of (choose one or mo ☐ GINA Board of Directors ☐ GINA Science Committee ☐ GINA Dissemination & Im ☐ GINA Advocate ☐ GINA Assembly	ĺ	ion Task Gr	oup		
Are there any relevant financi					
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
TOBACCO INDUSTRY FU	NDING				
☑ I declare that in the last 5 year electronic nicotine delivery system	m compan	ies that are w			
Signature: Brenda Los	uise Gi	iles			
Date: 04/19/2022	•				



Name:					
Member of (choose one or m ☐ GINA Board of Directors ☐ GINA Science Committee ☐ X GINA Dissemination & ☐ X GINA Advocate ☐ X GINA Assembly Are there any relevant finance	e z Implemen				
Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
Non		100	~ apporti		
NOII					
TOBACCO INDUSTRY F	UNDING				
☐ I declare that in the last 5 ye electronic nicotine delivery sys					
Signature:	negl				
organica.					
Date:January 2	20 th 2022				



Name: Le Thi Tuyet Lan	
Member of (choose one or more):	
☐ GINA Board of Directors	
☐ GINA Science Committee	
☐ GINA Dissemination & Implementation Task Gro	oup
☐ GINA Advocate	•
☑ GINA Assembly	

Are there any relevant financial interests to disclose?

Name of Entity	Grant?	Personal Fee?	Non-Financial Support?	Other?	Nature of involvement:
AstraZeneca	No	Yes	No	No	Honoraria
Boehringer Ingelheim	No	Yes	No	No	Honoraria
GlaxoSmithKline	No	Yes	No	No	Honoraria
Novartis	No	Yes	No	No	Honoraria

TOBACCO INDUSTRY FUNDING

☑ I declare that in the last 5 years, I have not received any funding from the tobacco industry or from electronic nicotine delivery system companies that are wholly or partially owned by tobacco companies.

Signature:

Date: 18th Jan 2022